Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

111.73
+1.961.79%
Post-market: 111.40-0.3347-0.30%16:15 EDT
Volume:5K
Turnover:540.15K
Market Cap:97.21M
PE:- -
High:112.38
Open:110.00
Low:109.95
Close:109.77
52wk High:126.40
52wk Low:55.34
Shares:870.00K
Float Shares:870.00K
Volume Ratio:0.33
T/O Rate:0.56%
Dividend:0.32
Dividend Rate:0.28%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals

TIPRANKS
·
Sep 01

Vertex Names Jonathan Poole CFO Effective Jan. 1, 2027

Reuters
·
Sep 01

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

THOMSON REUTERS
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

UK Regulator Suspends Avacopan Vifor for New Patients

MT Newswires Live
·
Sep 01

Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs

TIPRANKS
·
Sep 01

UK's Mhra : Informed Marketing Authorisation Holder of Decision to Suspend Use, Supply, Sale of Avacopan Vifor for New Patients from 1 September

THOMSON REUTERS
·
Sep 01

Why Is Amgen (AMGN) In Focus After New Repatha Survival Data?

Simply Wall St.
·
Sep 01

Vertex Advances Share Buyback, Acquires 445,500 Shares by August

TIPRANKS
·
Sep 01

Vertex (VRTX) Stock Looks Reasonable As Growth Must Justify Its Run

Simply Wall St.
·
Sep 01

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Sep 01

Political and General News Events from August 31

Reuters
·
Aug 31

Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients

MT Newswires Live
·
Aug 31

Amgen Repatha reduces risk of death in high-risk adults for first heart attack

TIPRANKS
·
Aug 31

Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke

THOMSON REUTERS
·
Aug 31

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Crinetics Shareholders Approve Vertex Acquisition at Special Meeting

TIPRANKS
·
Aug 29

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29